The Alzheimer's Accountability and Investment Act (Public Law 118-93), enacted on October 1, 2024, mandates that the National ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

Intra-Cellular’s promising clinical-stage pipeline includes treatments for a wide range of neurological indications.

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...

Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative ...

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL ...

To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...

Poorer cardiovascular health in childhood and adolescence may be linked to early differences in brain structure, particularly ...

A Potential Game-Changer for Mental Health TreatmentsSetting New Benchmarks: 65% Response Rate Shown in Completed Depression ...

Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...